THE SCIENCE
Targeted Protein Degradation
- Proteins are continuously synthesized and degraded in every cell. Disruption of the balance between synthesis and degradation of these
proteins could cause diseases including cancer. - The selective degradation of pathogenic proteins provides a powerful tool to kill cancerous cells or even restore the diseased cells to their
normal state.
InnoCure Therapeutics is developing PROTACs to destroy unwanted pathogenic proteins
- PROTACs (Proteolysis targeting chimeras) are small catalytic chemicals that link E3 ligases to pathogenic target proteins to induce their
degradation through the ubiquitin-proteasome system. PROTACs are then recycled to repeat the process. - Compared with direct inhibitors of target proteins, InnoCure’s Protein Degraders give enhanced selectivity and prolonged efficacy at
relatively low concentrations.
Targeted protein degradation using the Autosome Lysosome System
AUPTAC (Autophagy Targeting Chimera)
To enrich the toolboxes of targeted protein degradation, InnoCure Therapeutics has developed a new technology, AUPTAC
- AUPTAC is an innovative drug platform that takes advantage of the autophagy-lysosome degradation system that is found in every cell in
the body. Regardless of the size of the targets, it can break down the targeted intracellular proteins, damaged organelles, and lipid droplets. - AUPTAC is a hetero-bifunctional compound with two types of chemicals (a target protein binder and an autophagosome tethering protein
binder) connected by a linker.
TDbUM (Targeted Degradation by Ubiquitin Mediation) Discovery Platform
InnoCure Therapeutics is combining our biological expertise, AI processing, and medicinal chemistry skills to develop TDbUM, a unique
drug discovery platform to analyze 20,000+ human proteins of the human proteome identifying the ‘undruggable’ targets and discovering
binders for new E3 Ligases to expand our therapeutic targets and further increase our safety profile